



NEDO's "Research and Development Start-up Support Program" for FY2022

July 7, 2022

We are pleased to announce that the New Energy and Industrial Technology Development Organization (NEDO) has selected us as the grantee of the project on May 30, 2022.

(Major Criteria): Supporting R&D Startups

(Medium Criteria): Promotion of commercialization of start-up businesses

(Small Criteria) Development of a method for stable and durable expression of foreign genes

<https://www.nedo.go.jp/content/100949020.pdf>

GenAhead Bio. Inc is a biopharmaceutical company with proprietary nucleic acid delivery and genome editing technologies based on a wealth of experience. The genome-editing technology is applied to the treatment of intractable diseases. In addition, our genome-editing technology is used in the drug discovery research of pharmaceutical companies and bio-venture companies by producing disease model cells at a high rate through genetic transformation of normal cells. We are committed to the innovative healthcare business, and to the creation of a new innovation hub and are located in the Shonan Health Innovation Park, which is a center for innovative healthcare businesses and new innovations.

GenAhead Bio. Inc: <https://en.genaheadbio.co.jp/>

Shonan Health Innovation Park: <https://www.shonan-health-innovation-park.com/en>

For inquiries, please contact: info@genaheadbio.com